What is the price-to-earnings ratio of FibroGen?
The price-earnings ratio of FibroGen is currently 0.67.
FibroGen P/S 2024
FibroGen P/S
0.67
Ticker
FGEN
ISIN
US31572Q8087
WKN
A12EZ0
As of Sep 9, 2024, FibroGen's P/S ratio stood at 0.67, a -94.13% change from the 11.41 P/S ratio recorded in the previous year.
The FibroGen P/S history
FibroGen Aktienanalyse
What does FibroGen do?
FibroGen Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company is headquartered in San Francisco, California, with offices in China and Europe. Since its founding in 1993, the company has undergone remarkable development. It was founded by three doctors, Dr. Thomas B. Neff, Dr. Michael W. Loberg, and Dr. Gerald L. McMahon, who specialized in fibrosis and gene therapy. From the beginning, the company focused on research on therapies for diseases caused by abnormal connective tissue or fibrosis. FibroGen's business model is based on the innovation of therapies for the treatment of various diseases. The company has developed unique solutions that can improve the quality of life for people with severe chronic illnesses. To expand its business, FibroGen is supported by renowned partners, including Astellas Pharma, AstraZeneca, and Roche. FibroGen now has three business areas: biopharmaceuticals, China, and partnerships. In the biopharmaceuticals field, the company focuses on the development of therapies for the treatment of anemia in chronic kidney disease and idiopathic pulmonary fibrosis. One candidate, Roxadustat, is already approved in China and Japan and is currently being studied in clinical trials in the United States and Europe. Another candidate, Pamrevlumab, is marketed for the treatment of idiopathic pulmonary fibrosis. The Chinese market is particularly important for FibroGen, as the company has been active there since the early 2000s and has a subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. FibroGen has also signed an agreement with AstraZeneca in China to jointly develop and market Roxadustat. FibroGen's partnership business focuses on developing targeted therapies for diseases in collaboration with other pharmaceutical companies. Genentech, a subsidiary of Roche, is one of FibroGen's largest partners. The two companies work together to develop therapies for the treatment of diabetic retinopathy. FibroGen has made significant progress in recent years and received many awards. For example, in 2020, the company received the Prix Galien USA in the category of "Best Biopharmaceutical," an award for innovative drugs in improving public health. In summary, FibroGen is an innovative biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company's business model is focused on collaborations with partners to develop targeted therapies. With its subsidiaries in China and Europe, FibroGen can offer therapeutic solutions worldwide. FibroGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding FibroGen's P/S Ratio
FibroGen's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing FibroGen's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating FibroGen's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in FibroGen’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about FibroGen stock
How has the price-earnings ratio of FibroGen changed compared to last year?
The price-to-earnings ratio of FibroGen has increased by -94.13% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of FibroGen high compared to other companies?
Yes, the price-to-earnings ratio of FibroGen is high compared to other companies.
How does an increase in the price-earnings ratio of FibroGen affect the company?
An increase in the price-earnings ratio of FibroGen would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of FibroGen affect the company?
A decrease in the price-earnings ratio of FibroGen would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of FibroGen?
Some factors that influence the price-earnings ratio of FibroGen are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does FibroGen pay?
Over the past 12 months, FibroGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, FibroGen is expected to pay a dividend of 0 USD.
What is the dividend yield of FibroGen?
The current dividend yield of FibroGen is .
When does FibroGen pay dividends?
FibroGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of FibroGen?
FibroGen paid dividends every year for the past 0 years.
What is the dividend of FibroGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is FibroGen located?
FibroGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von FibroGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of FibroGen from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.
When did FibroGen pay the last dividend?
The last dividend was paid out on 9/9/2024.
What was the dividend of FibroGen in the year 2023?
In the year 2023, FibroGen distributed 0 USD as dividends.
In which currency does FibroGen pay out the dividend?
The dividends of FibroGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The FibroGen stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von FibroGen
Our stock analysis for FibroGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FibroGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
